Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

Influenza Clinical Trial

Official title:

A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) for the Treatment of Children Less Than 24 Months of Age With Confirmed Influenza Infection (CASG 114)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00391768
• Other study ID #: 06-0059
• Secondary ID: N01AI30025CRoche
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: October 20, 2006
• Last updated: April 25, 2013
• Start date: January 2007
• Est. completion date: April 2010

Study information

• Verified date: February 2010
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentCanada: Ethics Review CommitteeUnited States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to learn how to treat influenza in children less than 2 years of age. Tamiflu®, the drug being studied, is approved for treatment of children 1 year of age and older with influenza. Researchers want to learn more about the activity of Tamiflu® in the body to determine a dose of that is safe, well-tolerated, and effective in young children with influenza. Children less than 24 months of age with confirmed influenza will receive Tamiflu® 2 times a day for 5 days. Older participants will be enrolled first and younger children will be enrolled after the safety data is reviewed for older participants. Study procedures include blood samples, swabs from inside the nose, and body and nervous system evaluations. Participants may be involved in study related procedures for up to 37 days.

Description:

Oseltamivir is approved for prophylaxis and treatment of children 1 year of age and older with influenza. Influenza treatments for children under the age of 1 year are needed because mortality from influenza is high among this age group, even when there are no underlying medical conditions. Oseltamivir is frequently used off-label in children less than 1 year of age, with no data supporting the doses being used. Given the risk of severe or fatal influenza infection in infants, the lack of repeat dose pharmacokinetic (PK) data in children less than 2, the need for treatments in this population of children, and the fact that oseltamivir is being used off-label in this population, the current study will systematically study the PK and safety of oseltamivir in children less than 2 years of age with confirmed influenza to determine the appropriate dose to be used in these age groups. This data will be critical to pediatricians caring for these potentially gravely ill infants. This study is a prospective, age-stratified PK/pharmacodynamic (PD) and safety evaluation of oseltamivir therapy in children less than 24 months of age with confirmed influenza infection. Participants will be stratified by age into the following enrollment scheme at study initiation: 12-23 months (Cohort I), 9-11 months (Cohort II), 6-8 months (Cohort III), 3-5 months (Cohort IV) and 0-2 months (Cohort V). At study onset, Cohort II and III will be enrolled simultaneously. Cohorts IV and V will be enrolled sequentially by decreasing age groups predicated upon the PK and safety data from the preceding cohort. In the event of a public health emergency, the Data Safety Monitoring Board (DSMB) or Food and Drug Administration (FDA) may authorize the following modifications to the proposed enrollment plan: the opening of younger age cohorts without the full dataset from the next higher age cohort, the re-opening of previously closed cohorts to obtain additional data and/or the over-enrollment of any of the 5 cohorts. The oldest cohort (Cohort I) may be enrolled at any time during the study. The primary study objective is to define the PK of oseltamivir and oseltamivir carboxylate in children with confirmed influenza less than 2 years of age. The oseltamivir dose initially evaluated in Cohort I was the approved dose of 30 mg twice a day (bid). However, the oseltamivir carboxylate area under the curve (AUC)12 values for 5 of the 9 subjects enrolled in Cohort I as of August 5, 2009, were below the lower range utilized for the other cohorts in the study, as was the GM AUC12 for Cohort I as a group [(2589 nanograms per hour per milliliter (ngxh/mL)]. As a consequence, the DSMB recommended on August 5, 2009, that the protocol be amended to utilize weight-based dosing of oseltamivir in subjects subsequently enrolled in Cohort I, and to employ the targeted AUC approach used for Cohorts II-V for this cohort as well. Based upon the PK data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg bid. A dose of oseltamivir 3 mg/kg/dose orally bid for 5 days (10 doses) will be administered to the first 9 subjects in each of Cohorts II-III. Additional subjects may be enrolled if the target AUC12 range is not achieved. The proposed dose for subjects enrolled in Cohorts IV and V will be 3 mg/kg/dose orally bid for 5 days (10 doses), although this dose may be adjusted prior to opening Cohort IV or V based on the dose required to achieve the target oseltamivir carboxylate AUC12 range in the previous cohort.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: April 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 23 Months

Eligibility

Inclusion Criteria:

• Signed informed consent from parent(s) or legal guardian(s).

• Age:

Cohort I: 12 - 23 mo. Cohort II: 9 - 11 mo. Cohort III: 6 - 8 mo. Cohort IV: 3 - 5 mo. Cohort V: 0 - 2 mo.

• Confirmed laboratory diagnosis of influenza by viral culture or rapid influenza diagnostic test within 96 hours prior to study enrollment.

• Duration of influenza symptoms less than or equal to 96 hours.

Exclusion Criteria:

• Concomitant vomiting illness that would preclude ability to take drug.

• Immunocompromised subject (e.g., malignancy, congenital agammaglobulinemia, HIV).

• Documented renal impairment (e.g., polycystic renal disease, nephrectomy, renal transplantation, renal agenesis, dialysis requirement, renal failure, nephrotic syndrome at any time prior to enrollment, current receipt of diuretic therapy).

• Documented hepatic impairment (e.g., congenital hepatitis, biliary atresia, cholelithiasis).

• Gastrointestinal abnormality which might hinder absorption of an oral medication.

• Current receipt of inotropic drugs (e.g., epinephrine, norepinephrine, dopamine, dobutamine).

• History of seizures.

• Documented congenital malformations of the central nervous system defined at birth (e.g., hydranencephaly, prosencephaly, spina bifida).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Drug:
• oseltamivir (Tamiflu®)
Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.

Locations

Country	Name	City	State
Canada	University of Alberta Hospital - Pediatrics	Edmonton	Alberta
Canada	Centre Hospitalier de l'Universite Laval/ CHUQ	Quebec
Canada	The Hospital for Sick Children - Infectious Diseases	Toronto	Ontario
United States	Emory Children's Center - Pediatric Infectious Diseases	Atlanta	Georgia
United States	Emory University School of Medicine - Emory Children's Center - Pediatric Infectious Diseases	Atlanta	Georgia
United States	Children's Hospital Colorado - Infectious Disease	Aurora	Colorado
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Cincinnati Children's Hospital Medical Center - Infectious Diseases	Cincinnati	Ohio
United States	MetroHealth Medical Center - Pediatric Infectious Disease	Cleveland	Ohio
United States	Parkland Memorial Hospital	Dallas	Texas
United States	The University of Texas Southwestern Medical Center	Dallas	Texas
United States	Cook Children's Infectious Disease Services	Fort Worth	Texas
United States	University of Florida - Shands Children's Hospital	Gainesville	Florida
United States	University of Mississippi - Children's Infectious Diseases	Jackson	Mississippi
United States	Arkansas Children's Hospital - Infectious Diseases	Little Rock	Arkansas
United States	Miller Children's Hospital Long Beach - Bickerstaff Family Center	Long Beach	California
United States	Cohen Children's Medical Center - Pediatric Infectious Diseases	Manhasset	New York
United States	Vanderbilt University - Pediatric - Infectious Diseases	Nashville	Tennessee
United States	University of Nebraska Medical Center - Children's Hospital and Medical Center - Infectious Diseases	Omaha	Nebraska
United States	Children's Hospital of Orange County	Orange	California
United States	Children's Hospital of Philadelphia - The Center for Pediatric Clinical Effectiveness	Philadelphia	Pennsylvania
United States	Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric	Pittsburgh	Pennsylvania
United States	Rhode Island Hospital - Pediatrics	Providence	Rhode Island
United States	University of Rochester	Rochester	New York
United States	Washington University School of Medicine in St. Louis - Center for Clinical Studies	Saint Louis	Missouri
United States	University of Utah - Pediatric Pharmacology Program	Salt Lake City	Utah
United States	Rady Children's Hospital San Diego	San Diego	California
United States	Seattle Children's Hospital - Infectious Diseases	Seattle	Washington
United States	Louisiana State University Health Shreveport - Pediatrics	Shreveport	Louisiana
United States	SUNY Upstate Medical University Hospital - Pediatrics	Syracuse	New York
United States	University of South Florida - Tampa General Hospital - Pediatrics	Tampa	Florida
United States	Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

United States,  Canada, 

References & Publications (1)

Kimberlin DW, Acosta EP, Prichard MN, Sánchez PJ, Ampofo K, Lang D, Ashouri N, Vanchiere JA, Abzug MJ, Abughali N, Caserta MT, Englund JA, Sood SK, Spigarelli MG, Bradley JS, Lew J, Michaels MG, Wan W, Cloud G, Jester P, Lakeman FD, Whitley RJ; National I — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oseltamivir Carboxylate AUC12 (Area Under the Curve).	The oseltamivir carboxylate AUC12 was derived from a series of five blood draws over 10 to 12 hours.	Day 3 of drug administration	No
Secondary	Overall Reported Adverse Events (AEs) Thought to be Associated With Study Therapy.	Any event considered associated with drug that occurred post first dose of drug administration that was not present at baseline was considered an AE. Expected flu symptoms were not reported as AEs but were collected separately.	Duration of study, from receipt of the first dose of study drug and continuing through study visit Day 30 plus or minus 3 days.	Yes
Secondary	Number and Characteristics of Adverse Events (AEs) Described as Neurological Events.	Any neurological event that occurred post first dose of drug administration that was not present at baseline was considered an AE. Expected flu symptoms were not reported as AEs but were collected separately.	Duration of study, from receipt of the first dose of study drug and continuing through study visit Day 30 plus or minus 3 days.	Yes
Secondary	Incidence of Treatment Emergent AEs and Drug Related AEs by Cohort and Toxicity Grade	Any event considered to be related to the study drug that occurred post first dose of drug administration that was not present at baseline was considered an AE. Expected flu symptoms were not reported as AEs but were collected separately. The Division of AIDS Toxicity Tables (DIAIDS) were used to grade the events.	Duration of study, from receipt of the first dose of study drug and continuing through study visit Day 30 plus or minus 3 days	Yes
Secondary	Incidence of Treatment Emergent AEs and Drug Related AEs by Cohort Leading to Discontinuation of Study Medication	Study drug was administered for 5 days; any event that occurred prior to the last dose of study medication that was considered related to an AE and that caused the subject to stop taking study drug.	Duration of study, from receipt of the first dose of study drug and continuing through study visit Day 5 plus or minus 1 day	Yes
Secondary	Incidence of All Serious Adverse Events by Cohort and System Organ Class (SOC)	Serious Adverse Event (SAE) were classified by MedDRA System Organ Class (SOC). An SAE was reported if it met the following criteria and occurred after the first dose of study medication through the end of the study: death throughout study participation; life threatening; requires inpatient hospitalization or prolongation of existing hospitalization during the period of protocol defined surveillance; results in congenital anomaly or birth defect; results in a persistent or significant disability; and an event considered serious by the PI.	Duration of study, from receipt of the first dose of study drug and continuing through study visit Day 30 plus or minus 3 days	Yes
Secondary	Correlation of Clearance of Viral RNA by Culture With Pharmacokinetic Parameters by Cohort	The Spearman coefficient and the p-values were computed between the clearance of Viral RNA and Oseltamivir Carboxylate Area under the curve from 0 to 12 hours (AUC0-12)	Day to negative viral load for subjects positive at baseline	No
Secondary	Correlation of Clearance of Viral RNA by Polymerase Chain Reaction (PCR) to Pharmacokinetic Parameters by Cohort.	The Spearman coefficient and the p-values were computed between the clearance of viral RNA and oseltamivir carboxylate Area Under the Curve from 0 to 12 hours (AUC 0-12)	From date of enrollment until the date of first documented absence of viral load by culture, assessed up to 10 days after enrollment.	No